Benzinga -
- Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE in healthy volunteers.
- ARO-RAGE is an investigational RNA interference (RNAi) therapeutic designed to reduce the production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma.
- Also Read: Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
- Reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29:
- The mean maximum reduction at 92 mg dose was 80%, with a maximum reduction of 90%.
- Mean maximum reductions at 10 to 44 mg doses showed a dose response ranging from 31% to 59%.
- Reductions in serum sRAGE were also observed after a single dose:
- The mean maximum reduction at 92 mg dose was 56%, with a maximum reduction of 68%.
- Overall, no patterns of adverse changes in any clinical safety parameters were observed.
- There were no reported serious or severe adverse events.
- Also, there were no dropouts related to the drug or related to adverse events.
- Price Action: ARWR shares are up 13.70% at $34.14 on the last check Tuesday.